Price
No data yet.
Social Signal Score
Revenue
$14.31M-82.66%Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $42.17M | $-170.29M | $-1.45 |
| 2024 | $266.96M | $28.51M | $0.25 |
| 2023 | $257.24M | $-237.89M | $-2.53 |
| 2022 | $211.04M | $-291.75M | $-3.76 |
| 2021 | $326.55M | $-287.10M | $-3.81 |
Valuation
CHRShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80Social Signal Score
Mentions (1)
- Newsglobenewswire.com·5h ago·Negative
…oherus Oncology into a fully integrated, innovative immuno-oncology company – REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) (“Coherus”, “Coherus Oncology” or the “Company”) today announced a special dividend of contingent value rights (each, a “CVR” and collectively, the “CVRs”), which will be distributed on a pro rata basis to stockholders of record of the Company's common stock as of 5:00 p.m.
View source ↗
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $-0.21 per share
Typical surprise -3.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.19 vs $-0.25beat
- Mon, May 11$-0.25 vs $-0.26beat
- Mon, Mar 9$-0.34 vs $-0.36beat
- Thu, Nov 6$-0.33 vs $-0.32miss
- Thu, Aug 7$-0.34 vs $-0.31miss
- Mon, May 12$-0.35 vs $-0.31miss
Estimates and results for CHRS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CHRS officers and directors.
- Bought
- —
- Sold
- $524k
0 trades
2 trades
- Wahlstrom Matssold
- Lanfear Dennis Msold
98 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.